Innate Pharma Showcases Pre-IND Candidate IPH45's Preclinical Results at AACR 2024 - A New Antibody-Drug Conjugate Targeting Nectin-4.

Synthekine Unveils Encouraging Early Outcomes from Early-stage Clinical Study of Altered IL-2 Agent, STK-012, Aimed at Advanced Solid Cancer Therapy.

Obsidian Therapeutics Reveals Encouraging Safety and Effectiveness Results After 25 Weeks of Monitoring in Initial Human Trials for OBX-115.

CytomX Therapeutics has revealed initial treatment using CX-2051, a selective EpCAM-targeted antibody-drug conjugate, in an early-stage trial involving individuals with progressive solid malignancies.

CHS-1000, an Innovative ILT4 Antagonist Antibody, Showcased Through Early-Stage Research at AACR's 2024 Gathering.

Vivet Therapeutics Administers Initial Dose to First Participant in Second Group of Phase 1/2 GATEWAY Study for Wilson Disease Therapy.

Promising Early Results for SCB-1019 Vaccine in Young Adults: Clover Biopharmaceuticals Phase I Insights.

Ichnos Glenmark Innovation Unveils Early Findings for Cancer Candidate ISB 2001 at AACR 2024.

Mabwell has declared that its fully-owned subsidiary, T-mab, has successfully received the green light for its Denosumab Injection from the National Medical Products Administration.

Primary Objectives Achieved in Stage 3 Trial for HLX14, a Biosimilar Contender to Prolia® and Xgeva® (denosumab).

Ferring Unveils Key Phase 3 Results for Experimental Therapy, SI-6603 (condoliase), in Treating Lower Back Disc Protrusion during ASIPP 2024.

U.S. Sanctions ENHERTU®, a Pioneer HER2-Targeting Drug, for Metastatic Solid Cancers with HER2 Positivity After Initial Treatments.